Latest Pharma and Biotech News
Pharmaceutical
26 June 2025 In a sector where regulation is tight and reputation is paramount, bold, purposeful leadership has never been more necessary, writes Alessandro Buccella of Heidrick & Struggles, in an Expert View.
Today's issue
Refine Search
Biotechnology
US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. 26 June 2025
Generics
US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb, accusing the drugmaker of manipulating the patent system to preserve its monopoly on the multiple myeloma treatment Pomalyst (pomalidomide). 26 June 2025
Biotechnology
Singapore-based biotech Hummingbird Bioscience has out-licensed its lead immunotherapy candidate, HMBD-002, to Australian drug developer Percheron Therapeutics in a deal valued at up to $290 million. 26 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has required and approved updates to the Prescribing Information for Comirnaty (COVID-19 Vaccine, mRNA) manufactured by Pfizer and Spikevax (COVID-19 Vaccine, mRNA) manufactured Moderna to include new safety information about the risks of myocarditis and pericarditis following administration of mRNA COVID-19 vaccines. 26 June 2025
Biotechnology
Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry Platform. 26 June 2025
Biotechnology
Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim findings from a Phase I study. 26 June 2025
Biotechnology
Australian biotech CSL Limited Europe-based subsidiary CSL Behring announced a milestone in the early benefit assessment of garadacimab by Germany’s Institute for Quality and Efficiency in Health Care (IQWiG). 26 June 2025
Biotechnology
Bayer’s cell therapy subsidiary BlueRock Therapeutics is shifting its priorities, cutting around 50 jobs and shutting its research labs in Massachusetts to streamline operations and concentrate on advanced-stage programs. 26 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (previously known as EG-70), Canadian company enGene’s lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). 26 June 2025
Pharmaceutical
In a sector where regulation is tight and reputation is paramount, bold, purposeful leadership has never been more necessary, writes Alessandro Buccella of Heidrick & Struggles, in an Expert View. 26 June 2025
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the trade name for Neffy in the European Union) in Germany. 26 June 2025
Biotechnology
PureTech Heath founded clinical-stage biotech Vor Bio has entered into an exclusive license agreement with RemeGen to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). 26 June 2025
Biotechnology
Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine prevention study showed that Ajovy (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in cutting frequency, duration and severity of attacks in chronic and episodic migraine. 25 June 2025
Biotechnology
Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or chronic primary immune thrombocytopenia (ITP). 25 June 2025
Biotechnology
US biotech PTC Therapeutics’ (Nasdaq: PTCT) Sephience (sepiapterin) has been granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU). The authorization includes a broad label inclusive of all ages and disease severities. 25 June 2025
Generics
Israeli generics major Teva Pharmaceutical Industries has highlighted that Europe is experiencing increasing pressure on its medicines supply. 25 June 2025
Biotechnology
In a busy day for the US drugmaker, Kymera Therapeutics yesterday announced a licensing deal with Gilead Sciences updated on its collaboration with French pharma major Sanofi. 25 June 2025
Pharmaceutical
Republican Senator Bill Cassidy has called for Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) to be delayed. 25 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Pharmaceutical
The UK government has unveiled a sweeping industrial strategy aimed at catapulting the country into the top tier of global life sciences economies by 2035. Positioned as one of eight growth sectors, life sciences is set to benefit from a multibillion-dollar push to streamline regulation, enhance health data infrastructure, and accelerate innovation. 25 June 2025
All news
Biotechnology
US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. 26 June 2025
Generics
US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb, accusing the drugmaker of manipulating the patent system to preserve its monopoly on the multiple myeloma treatment Pomalyst (pomalidomide). 26 June 2025
Biotechnology
Singapore-based biotech Hummingbird Bioscience has out-licensed its lead immunotherapy candidate, HMBD-002, to Australian drug developer Percheron Therapeutics in a deal valued at up to $290 million. 26 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has required and approved updates to the Prescribing Information for Comirnaty (COVID-19 Vaccine, mRNA) manufactured by Pfizer and Spikevax (COVID-19 Vaccine, mRNA) manufactured Moderna to include new safety information about the risks of myocarditis and pericarditis following administration of mRNA COVID-19 vaccines. 26 June 2025
Biotechnology
Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry Platform. 26 June 2025
Biotechnology
Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim findings from a Phase I study. 26 June 2025
Biotechnology
Australian biotech CSL Limited Europe-based subsidiary CSL Behring announced a milestone in the early benefit assessment of garadacimab by Germany’s Institute for Quality and Efficiency in Health Care (IQWiG). 26 June 2025
Biotechnology
Bayer’s cell therapy subsidiary BlueRock Therapeutics is shifting its priorities, cutting around 50 jobs and shutting its research labs in Massachusetts to streamline operations and concentrate on advanced-stage programs. 26 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (previously known as EG-70), Canadian company enGene’s lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). 26 June 2025
Pharmaceutical
In a sector where regulation is tight and reputation is paramount, bold, purposeful leadership has never been more necessary, writes Alessandro Buccella of Heidrick & Struggles, in an Expert View. 26 June 2025
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the trade name for Neffy in the European Union) in Germany. 26 June 2025
Biotechnology
PureTech Heath founded clinical-stage biotech Vor Bio has entered into an exclusive license agreement with RemeGen to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). 26 June 2025
Biotechnology
Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine prevention study showed that Ajovy (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in cutting frequency, duration and severity of attacks in chronic and episodic migraine. 25 June 2025
Biotechnology
Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or chronic primary immune thrombocytopenia (ITP). 25 June 2025
Biotechnology
US biotech PTC Therapeutics’ (Nasdaq: PTCT) Sephience (sepiapterin) has been granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU). The authorization includes a broad label inclusive of all ages and disease severities. 25 June 2025
Generics
Israeli generics major Teva Pharmaceutical Industries has highlighted that Europe is experiencing increasing pressure on its medicines supply. 25 June 2025
Biotechnology
In a busy day for the US drugmaker, Kymera Therapeutics yesterday announced a licensing deal with Gilead Sciences updated on its collaboration with French pharma major Sanofi. 25 June 2025
Pharmaceutical
Republican Senator Bill Cassidy has called for Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) to be delayed. 25 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Pharmaceutical
The UK government has unveiled a sweeping industrial strategy aimed at catapulting the country into the top tier of global life sciences economies by 2035. Positioned as one of eight growth sectors, life sciences is set to benefit from a multibillion-dollar push to streamline regulation, enhance health data infrastructure, and accelerate innovation. 25 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze